Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2011-06-09 Share Issue/Capital Cha…
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
Cleansing Statement 1 page 25.7KB
Share Issue/Capital Change Classification · 95% confidence The document is a notice under Section 708A(5)(e) of the Corporations Act regarding the issuance of fully paid ordinary shares without disclosure under Part 6D.2 of the Corporations Act. It is a regulatory announcement about a share issue event but does not contain financial statements or detailed financial data. The document length is short (1181 characters) and it is a formal notification to the market about compliance and share issuance. This fits the category of Share Issue/Capital Change announcements rather than a full financial report or other types of filings.
2011-06-09 English
1st Presentation by Pr. R Elliott to IPITA World Conference 19 pages 1.5MB
Regulatory Filings
2011-06-07 English
2nd Presentation by Pr. R Elliott to IPITA World Conference 25 pages 681.2KB
Regulatory Filings Classification · 95% confidence The document is a detailed scientific and medical report focusing on managing potential zoonotic infections in swine-to-human islet xenotransplants. It includes extensive data tables, screening protocols, patient follow-up information, microbiological testing, and serology results. There is no indication of corporate financial data, regulatory filings, management changes, earnings, or capital structure updates. The content is highly specialized and technical, related to medical research rather than corporate financial or governance matters. It does not fit any of the financial or corporate filing categories such as Annual Report, Earnings Release, or Regulatory Filings. Given the nature of the content, it is best classified under Regulatory Filings (RNS) as a fallback category for miscellaneous filings that do not fit other specific categories.
2011-06-07 English
Appendix 3B 8 pages 134.9KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new ordinary shares, including the number of shares, issue price, purpose of the issue, and quotation application to the ASX (Australian Securities Exchange). It references specific ASX rules (2.7, 3.10.3, 3.10.4, 3.10.5) and includes sections typical of a new issue announcement such as securities ranking, issue price, purpose, and quotation agreement. The document is a formal announcement of a new share issue and application for quotation rather than a full financial report or earnings release. It is not a report but an announcement of capital raising activity and securities issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (over 10,000 characters) supports it being a full announcement rather than a brief notice.
2011-06-07 English
Cleansing Statement 1 page 28.8KB
Share Issue/Capital Change Classification · 100% confidence The document is a notice under Section 708A(5)(e) of the Corporations Act regarding the issuance of 6,000,000 fully paid ordinary shares by Living Cell Technologies Limited. It is a formal announcement about a share issue without disclosure under Part 6D.2 of the Corporations Act. The content focuses on compliance and disclosure related to the share issuance, not on financial results or detailed reports. The document length is short (1185 characters) and it is clearly an announcement of a capital transaction rather than a full report. Therefore, it fits the category of Share Issue/Capital Change (SHA).
2011-06-07 English
Results of General Meeting 3 pages 47.2KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled 'Results of the General Meeting held on 7 June 2011' and provides detailed voting results for multiple resolutions passed at the General Meeting of Living Cell Technologies Limited. It includes specific proxy vote counts for each resolution and references compliance with ASX Listing Rules and the Corporations Act. The content focuses on the official announcement of shareholder voting outcomes rather than the meeting materials, presentations, or the meeting itself. There is no financial data, management discussion, or report attached, only the voting results. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document length is 7986 characters, sufficient to contain detailed voting results, not just a brief announcement or a report publication notice. Therefore, the correct classification is DVA with high confidence.
2011-06-06 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.